![News](https://www.valicare.com/hs-fs/hubfs/02_news/Laptop.jpg?width=412&height=236&name=Laptop.jpg)
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/the-labyrinth-guideline.jpg?width=270&height=152&name=the-labyrinth-guideline.jpg)
Novelties by EMA on medicinal products with genetically modified cells
Updated EMA guideline for medicinal products containing genetically modified cells provides innovations, recommendations and improvements to be ...
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/laptop.jpg?width=270&height=152&name=laptop.jpg)
Toxicological assessment gain acceptance for cleaning validation
WHO publishes decision on setting acceptance criteria for cleaning validation
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/laptop.jpg?width=270&height=152&name=laptop.jpg)
FDA approves Breyanzi®, a new CAR-T cell therapy drug
Fourth approved CAR-T cell therapy soon to be available in Europe?
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/mrna-based-vaccines.jpg?width=270&height=152&name=mrna-based-vaccines.jpg)
Vaccinations with mRNA-based medicinal products
How do mRNA-based medicinal products work and how safe are they?
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/efficiency-compass.jpg?width=270&height=152&name=efficiency-compass.jpg)
Integrated Qualification and Validation Guide
New ECA guide helps saving time and money by customer-supplier partnership on qualification and validation.
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/blue-pills.jpg?width=270&height=152&name=blue-pills.jpg)
Nitrosamines in active substances and finished medicinal products
EMA strongly requests the risk-based proof that active substances and finished medicinal products are free of nitrosamines. Are you prepared for this?
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/laptop.jpg?width=270&height=152&name=laptop.jpg)
Valicare Extends GxP Expertise
New Consulting Services for the Transition from Development to Clinical Manufacturing
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/laptop.jpg?width=270&height=152&name=laptop.jpg)
MSC & Covid-19
In order to identify approaches to manage the current Covid-19 pandemic, the therapeutic use of mesenchymal stromal cells (MSCs) is increasingly ...
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/laptop.jpg?width=270&height=152&name=laptop.jpg)
FDA opens up approval process for RYONCYL™
Mesoblast Ltd, headquartered in Australia with subsidiaries in the USA and Singapore, develops and distributes innovative allogenic cell therapeutics ...
![Blog](https://www.valicare.com/hs-fs/hubfs/02_news/fda-approved.jpg?width=270&height=152&name=fda-approved.jpg)
FDA approves CAR T-cell therapy Tecartus™
On July 24, 2020, the US health authority FDA approved Tecartus™ (formerly KTE-X19) a cell-based gene therapy based on the chimeric antigen receptor ...
![Blog](https://www.valicare.com/hs-fs/hubfs/gmp-for-atmps-teaser.jpg?width=270&height=152&name=gmp-for-atmps-teaser.jpg)
Use public funding for consulting services!
We’re in! Valicare is now an official BAFA-consultant and can tell you how consulting costs for small and medium-sized companies can be reduced.